文献速递白血病

CBFA2T3::GLIS2儿童急性巨核细胞白血病对navitoclax和DT2216抑制BCL-XL敏感

CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.
PubMed 文献 · Blood Adv · 2024-01-01

本研究建立CD34+脐血来源的CBFA2T3::GLIS2(CG2)急性巨核细胞白血病(AMKL)模型(n=6),模型可连续移植并重现人白血病特征。CG2细胞对BCL2抑制(venetoclax或BCL2敲低)相对耐药,但对靶向BCL-XL的策略敏感,navitoclax和DT2216在体外和体内均有效;NUP98r AMKL也敏感,而NUP98r单核细胞白血病不敏感。navitoclax或DT2216联合低剂量阿糖胞苷进一步降低小鼠白血病负荷。

要点

  • CD34+脐血来源CG2模型(n=6)可连续移植并重现人AMKL免疫表型、白血病起始细胞频率、突变图谱和基因表达特征。
  • CG2细胞对BCL2敲低或venetoclax相对耐药,但对BCL-XL靶向策略(navitoclax、DT2216)敏感。
  • NUP98r AMKL对BCL-XL抑制敏感,而NUP98r单核细胞白血病不敏感,提示谱系特异性依赖。

核心结论

  • 本研究扩展了人AMKL模型的细胞和分子多样性,并发现BCL-XL是CG2和NUP98r AMKL的治疗脆弱点。

研究设计与样本

  • 研究建立CD34+脐血来源的CG2模型(n=6),模型可连续移植并重现人白血病的免疫表型、白血病起始细胞频率、突变图谱和基因表达特征。
  • 采用细胞膜蛋白质组学分析CG2表面标志物,并用单细胞 profiling 确认AMKL在巨核-红系祖细胞空间的分化阻滞。
  • 在体外和体内评估navitoclax、DT2216及联合低剂量阿糖胞苷的疗效,并比较NUP98r AMKL与NUP98r单核细胞白血病的敏感性。

主要发现

  • CG2模型显示促存活因子B细胞淋巴瘤2(BCL2)上调,且CG2细胞对BCL2基因敲低或venetoclax选择性药理抑制相对耐药。
  • CG2细胞对靶向巨核细胞促存活因子BCL-XL(BCL2L1)的策略敏感,包括体外和体内使用BCL2/BCL-XL/BCL-W抑制剂navitoclax和选择性BCL-XL蛋白水解靶向嵌合体降解剂DT2216。
  • NUP98r AMKL对BCL-XL抑制也敏感,但NUP98r单核细胞白血病不敏感,提示谱系特异性依赖。
  • navitoclax或DT2216联合低剂量阿糖胞苷进一步降低小鼠白血病负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted, and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery of cell- and genotype-specific treatments. AMKL is driven by mutually exclusive chimeric fusion oncogenes in two-thirds of the cases, with CBFA2T3::GLIS2 (CG2) and NUP98 fusions (NUP98r) representing the highest-fatality subgroups. We established CD34+ cord blood-derived CG2 models (n = 6) that sustain serial transplantation and recapitulate human leukemia regarding immunophenotype, leukemia-initiating cell frequencies, comutational landscape, and gene expression signature, with distinct upregulation of the prosurvival factor B-cell lymphoma 2 (BCL2). Cell membrane proteomic analyses highlighted CG2 surface markers preferentially expressed on leukemic cells compared with CD34+ cells (eg, NCAM1 and CD151). AMKL differentiation block in the mega-erythroid progenitor space was confirmed by single-cell profiling. Although CG2 cells were rather resistant to BCL2 genetic knockdown or selective pharmacological inhibition with venetoclax, they were vulnerable to strategies that target the megakaryocytic prosurvival factor BCL-XL (BCL2L1), including in vitro and in vivo treatment with BCL2/BCL-XL/BCL-W inhibitor navitoclax and DT2216, a selective BCL-XL proteolysis-targeting chimera degrader developed to limit thrombocytopenia in patients. NUP98r AMKL were also sensitive to BCL-XL inhibition but not the NUP98r monocytic leukemia, pointing to a lineage-specific dependency. Navitoclax or DT2216 treatment in combination with low-dose cytarabine further reduced leukemic burden in mice. This work extends the cellular and molecular diversity set of human AMKL models and uncovers BCL-XL as a therapeutic vulnerability in CG2 and NUP98r AMKL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gress V, Roussy M, Boulianne L, et al. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216. Blood Adv. 2024. PMID: 37729615. doi:10.1182/bloodadvances.2022008899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。